Given that most chemotherapy regimens achieve comparable EFS rates, the optimal front‐line therapy for ALK‐positive ALCL can be considered the regimen that offers the shortest duration of therapy with the lowest cumulative doses of agents associated with a high risk of late effects. Here, ALK is linked to anaplastic large cell lymphoma.